复杂的生物批准过程延迟了中度至重度喘患者的护理
Esha Sehanobish1, Kenny Ye1, Kamran Imam2
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
The journal of allergy and clinical immunology. Global
|October 2, 2023
概括
治疗严重喘的生物药物需要大量的临床努力才能获得事先授权. 生物批准和管理的延迟是常见的,受上诉程序和保险覆盖的影响.
科学领域:
- 肺部病理学 肺部病理学
- 临床药房 临床药房
背景情况:
- 单克隆抗体 (生物药物) 对于管理中度至重度喘至关重要.
- 生物制剂的预先授权和管理需要大量的临床资源.
研究的目的:
- 分析喘患者生物药物的批准和施用途径.
- 确定生物拒绝和管理延迟的主要原因.
主要方法:
- 从2018年1月到2020年1月在两个不同的医疗保健中心对喘患者的电子健康记录进行了回顾性审查,这些患者从2018年1月到2020年1月处方生物药.
- 数据收集包括患者人口统计,保险详细信息和审批过程时间表.
主要成果:
- 总共包括422名患者 (352名来自蒙特菲奥雷,70名来自斯克里普斯).
- 在两个中心中,处方至施用的中位时间相似 (34天).
- 审批时间的中位数显著不同 (蒙特菲奥雷:6天;斯克里普斯:22天),上诉大幅增加这些时间 (例如,斯克里普斯的40.5天).
结论:
- 延长的上诉程序显著延长了生物药物处方和管理之间的时间.
- 特定地点实践和保险覆盖的变化会影响喘患者的生物批准时间表.
相关概念视频
Antiasthma Drugs: β2-Adrenoceptor Agonists
290
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
290
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338


